Citations

Showing 10 of 108152 citations.

Is Autologous Stem Cell Transplantation a Safe and Effective Alternative to Whole Brain Radiation as Consolidation Therapy in Patients With Primary Central Nervous System Lymphoma?
Gritsch, David , Mrugała, Maciej M. , Marks, Lisa , Mangipudi, Kartik, Neal, Matthew T. , Wingerchuk, Dean M. , O’Carroll, Cumara B. , Marks, Lisa A

Mayo Clinic

The Neurologist | June 30, 2021 | Volume: 26 | Issue: 4 | Pages: 137-142

10.1097/nrl.0000000000000328 | PMID 34190207 Get It

Background: High-dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) is a promising alternative to whole brain radiation therapy (WBRT) in the treatment of primary central nervous system lymphoma (PCNSL). The objective of this study was to critically assess current evidence supporting the use of HD-ASCT as first-line consolidative therapy in PCNSL. Methods: The objective was addressed through the development of a critically appraised topic that included a clinical scenario, structured question, literature search strategy, critical appraisal, assessment of results, evidence summary, commentary, and bottom-line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and a content expert in the field of neuro-oncology. Results: A recent, open-label, noncomparative randomized phase II trial was selected for critical appraisal. This trial evaluated the efficacy and toxicity of consolidative therapy with HD-ASCT and WBRT in PCNSL in 2 separate treatment arms. A total of 140 patients with newly diagnosed PCNSL between the ages of 18 and 60 years were included. The primary endpoint of 2-year progression-free survival was met in 63% of patients in the WBRT arm and 87% in the HD-ASCT arm. Notably, an overall improvement in neurocognitive scores was observed following HD-ASCT, while WBRT was associated with worsened cognitive outcomes. Conclusions: In young patients with newly diagnosed PCNSL, consolidative therapy with HD-ASCT appears to be associated with less neurocognitive toxicity and may be more effective than WBRT at preventing relapses, however, at the cost of a higher treatment-related mortality.
Outcomes among patients with COVID-19 and asthma: A systematic review and meta-analysis
Sitek, Andrea , Ade, Justine M. , Divekar, Rohit , Pitlick, Mitchell M. , Joshi, Avni Y. , Sitek, Andrea N, Divekar, Rohit D, Chiarella, Sergio E. , Iyer, Vivek , Wang, Zhen

Mayo Clinic

Allergy and Asthma Proceedings | June 30, 2021 | Volume: 42 | Issue: 4 | Pages: 267-273

10.2500/aap.2021.42.210041 | PMID 34187619 Get It

Background: It remains unclear if asthma is a risk factor associated with worse outcomes among patients with coronavirus disease 2019 (COVID-19). Methods: We performed a comprehensive database search for studies published from January 1, 2019, to October 2, 2020. We included studies that evaluated outcomes among patients with COVID-19 and underlying asthma. Outcomes of interest included the need for hospitalization, length of hospitalization, intensive care unit (ICU) admission, and death. The meta-analysis was conducted by using random-effects methodology. Results: A total of 389 studies were identified through data base searches. After abstract and full-text screening, 16 observational studies with 92,275 patients were included in the analysis. Of the 16 studies, 15 were retrospective and 1 was a prospective cohort study. The average age was 39.6 years, with 48% female patients. Six of the studies included pediatric patients, and one of these studies only evaluated pediatric patients. One study only evaluated pregnant patients. Among patients with COVID-19, the presence of asthma was not associated with any significant increase in risk of hospitalization (odds ratio [OR] 1.46 [95% confidence interval {CI}, 0.29-7.28]), length of hospitalization (1.59 days [‐0.55 to 3.74]), ICU admission (OR 1.65 [95% CI, 0.56-4.17]), or death (OR 0.73 [95% CI, 0.38-1.40]). The overall risk of bias of the included studies was high. Conclusion: Among the patients with COVID-19, asthma did not seem to significantly increase the risk of hospitalization, length of hospitalization, ICU admission, or death.
Revascularization in Patients With Spontaneous Coronary Artery Dissection: Where Are We Now?
Krittanawong, Chayakrit , Gulati, Rajiv , Eitzman, Daniel T. , Jneid, Hani

Mayo Clinic

Journal of the American Heart Association | June 30, 2021 | Volume: 10 | Issue: 13 | Pages: No page available

10.1161/jaha.120.018551 | PMID 34187166 Get It

Novel Variant in CLDN16: A Further Step in the Diagnosis of Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis—A Case Report
Shimon, Tim, Hager, Megan M., Vairo, Filippo Pinto e , Keddis, Mira T. , Humphreys, Mitchell R. , Vairo, Filippo , Narang, Gopal , Moore, Jonathan, Stern, Karen

Mayo Clinic

Uro | June 30, 2021 | Volume: 1 | Issue: 3 | Pages: 76-81

10.3390/uro1030011 Get It

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is a rare tubulopathy characterized by renal loss of calcium and magnesium leading to progressive renal failure. The disorder is caused by variants to the tight junction proteins claudin-16 and -19. While rare, this disorder causes a significant burden to patients based on its clinical manifestations of various electrolyte abnormalities, nephrocalcinosis, and early progression to renal failure. In this report we describe the diagnosis of a novel variant of CLDN16 which clinically presented with severe hypomagnesemia, hypocalcemia, nephrocalcinosis, and renal failure.
NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer
Yuan, Yuan , Gao, Huanyao , Zhuang, Yongxian , Wei, Lixuan , Yu, Jia , Zhang, Zhe , Zhang, Lili , Wang, Liewei

Mayo Clinic

Therapeutic Advances in Medical Oncology | June 30, 2021 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/17588359211027836 | PMID 34276814 Get It

Background: Trastuzumab (Herceptin) is the key systemic therapy for HER2-positive breast cancer. However, the initial response rate is limited to approximately 50% in patients. Moreover, most patients, especially at an advanced stage, eventually develop acquired resistance. Understanding the mechanisms of trastuzumab resistance is crucial for achieving better treatment outcome in this group of patients. Methods: A trastuzumab-resistant (TR) cell line was developed using the BT474 HER2-positive breast cancer cell line. Whole-transcriptome expression array was performed and the TR-related gene NDUFA4L2 was identified by differential expression analysis between BT474 and BT474-TR. Mitochondrial localization of NDUFA4L2 was confirmed by immunofluorescence and western blotting using mitochondrial fractionation. Mitochondrial function and energy metabolism were evaluated using Seahorse, ATP production, and lactate production assays, and cellular reactive oxygen species (ROS) levels were determined using DCFDA. NDUFA4L2 expression in patients was evaluated by immunohistochemistry, and relapse-free survival was analyzed using the Kaplan–Meier method. Results: NDUFA4L2 was highly expressed in the TR HER2-positive breast cancer cell line. High expression level of NDUFA4L2 was associated with shorter relapse-free intervals in trastuzumab-treated HER2-positive breast cancer patients. Overexpression of NDUFA4L2 enhanced Warburg effects, enhanced aerobic glycolysis, reduced oxygen consumption, and lowered ROS production. Mechanistically, overexpression of NDUFA4L2 facilitated mitochondrial relocalization of HER2 and suppressed ROS production, thus rendering cancer cells more resistant to trastuzumab treatment. Conclusions: We identified NDUFA4L2 as a new biomarker and potential therapeutic target for TR HER2-positive breast cancer.
Response to Marlicz et al.
Pawa, Swati , Burke, Carol A. , Oxentenko, Amy S. , Burke, Carol A

Mayo Clinic

American Journal of Gastroenterology | June 30, 2021 | Volume: 116 | Issue: 9 | Pages: 1961-1963

10.14309/ajg.0000000000001360 | PMID 34188011 Get It

Response to Albuquerque et al.
Vegunta, Suneela , Whited, M. Helen, Long, Margaret E. , Shah, Amit A, Shah, Amit

Mayo Clinic

American Journal of Gastroenterology | June 30, 2021 | Volume: 116 | Issue: 10 | Pages: 2140-2141

10.14309/ajg.0000000000001368 | PMID 34187980 Get It

Distal Femoral Replacement for Fractures Allows for Early Mobilization with Low Complication Rates: A Multicenter Review
Stancil, Ryan , Romm, Jacob, Lack, William D. , Bohnenkamp, Frank, Sems, S.A. , Cross, William W., Cass, Joseph R., Keeney, James A. , Nam, Denis , Nunley, Ryan M. , Fernando, Navin , Sassoon, Adam , Sems, Stephen, Cross, William, Cass, Joseph, Keeney, James

Mayo Clinic

The Journal of Knee Surgery | June 29, 2021 | Volume: 36 | Issue: 02 | Pages: 146-152

10.1055/s-0041-1731353 | PMID 34187069 Get It

AbstractPeriprosthetic fractures around a total knee arthroplasty (TKA), comminuted and intra-articular femur fractures, or fracture nonunions in osteoporotic bone represent technically challenging problems. This is particularly true when the fracture involves a loose femoral component or the pattern results in suboptimal fixation potential. These clinical indications often arise in an older and comorbid patient population in whom a principal goal of treatment includes allowing for early mobilization. Limited data indicate that arthroplasty via distal femoral replacement (DFR) is a reasonable alternative to open reduction and internal fixation, allowing for early ambulation with low complication rates. We performed a retrospective review of trauma and arthroplasty surgeries at three tertiary referral institutions. Adult patients treated for the above with a DFR were included. Patients with active infection, open and/or high-energy injuries and revisions unrelated to fracture were excluded. Patient demographics, treatment details, and outcomes were assessed. Between 2002 and 2017, 90 DFR's were performed for the above indications with a mean follow-up of 24 months. Postoperatively, 80 patients (88%) were allowed to weight bear as tolerated, and at final follow-up, 9 patients (10%) remained dependent on a wheelchair. The average arc of motion at final follow-up was 95 degrees. There were seven (8%) implant-related complications requiring secondary surgeries: two infections, one with associated component loosening; one fracture of the hinge mechanism and one femoral component failure in conjunction with a patellofemoral dislocation (both requiring revision); one case of patellofemoral arthrosis in a patient with an unresurfaced patella; one periprosthetic fracture with associated wound dehiscence; and one case of arthrofibrosis. In each of these cases, only modular components of the DFR were exchanged. All nonmodular components cemented into the femur or tibia were retained. DFR provides a viable reconstruction option in the treatment of acute distal femur fractures, periprosthetic femur fractures, and fracture nonunions. We noted that in an elderly patient population with high comorbidities, the complication and secondary surgery rates remained relatively low, while allowing for immediate weight bearing.
The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies
Liu, Dan , Belleghem, Jonas D. Van , Vries, Christiaan R. de , Burgener, Elizabeth B. , Chen, Qingquan , Manasherob, Robert , Aronson, Jenny, Amanatullah, Derek F. , Suh, Gina A. , Van Belleghem, Jonas D , de Vries, Christiaan R , Suh, Gina A , Tamma, Pranita D.

Mayo Clinic

Viruses | June 29, 2021 | Volume: 13 | Issue: 7 | Pages: 1268

10.3390/v13071268 | PMID 34209836 Get It

Increasing rates of infection by antibiotic resistant bacteria have led to a resurgence of interest in bacteriophage (phage) therapy. Several phage therapy studies in animals and humans have been completed over the last two decades. We conducted a systematic review of safety and toxicity data associated with phage therapy in both animals and humans reported in English language publications from 2008–2021. Overall, 69 publications met our eligibility criteria including 20 animal studies, 35 clinical case reports or case series, and 14 clinical trials. After summarizing safety and toxicity data from these publications, we discuss potential approaches to optimize safety and toxicity monitoring with the therapeutic use of phage moving forward. In our systematic review of the literature, we found some adverse events associated with phage therapy, but serious events were extremely rare. Comprehensive and standardized reporting of potential toxicities associated with phage therapy has generally been lacking in the published literature. Structured safety and tolerability endpoints are necessary when phages are administered as anti-infective therapeutics.
Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy—A Case Report
Leis, José F., Patel, B. M. , Sen, Ayan , Leis, Jose, Singbartl, Kai , Rosenthal, Allison

Mayo Clinic

Critical Care Explorations | June 29, 2021 | Volume: 3 | Issue: 7 | Pages: e0472

10.1097/cce.0000000000000472 | PMID 34235458 Get It

BACKGROUND: Chimeric antigen receptor T-cell therapies (CAR-T) are transforming the treatment of B-cell leukemias and lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent common, potentially life-threatening toxicities from chimeric antigen receptor T-cell therapy treatment. CASE SUMMARY: We present a 53-year-old patient with primary refractory high-grade B-cell lymphoma who developed severe, refractory neurotoxicity following chimeric antigen receptor T-cell therapy but exhibited complete recovery after extracorporeal blood purification with CytoSorb (CytoSorbents, Monmouth Junction, NJ). Six days after chimeric antigen receptor T-cell therapy infusion, the patient developed cytokine release syndrome grade 3, prompting administration of dexamethasone and tocilizumab, a monoclonal antibody against the interleukin-6 receptor. His C-reactive protein levels started to decrease with tocilizumab and dexamethasone treatments. However, his ferritin levels continued to rise, and his interleukin-6 levels were above the upper detection threshold. Thirty-six hours later, the patient showed improved cytokine release syndrome but developed severe immune effector cell-associated neurotoxicity syndrome with predominant encephalopathy (grade 3) despite treatment with dexamethasone/methylprednisolone, tocilizumab, and anakinra. We therefore sought a rescue strategy to remove inflammatory mediators. Following emergency use authorization, we initiated extracorporeal blood purification with CytoSorb (CytoSorbents). Four-day extracorporeal blood purification resulted in complete resolution of immune effector cell-associated neurotoxicity syndrome and greater than 95% reduction in interleukin-6 levels without side effects. The patient was discharged home 10 days later with no signs of neurotoxicity or other secondary end-organ dysfunction. CONCLUSIONS: Our case represents the first reported, successful application of extracorporeal blood purification with CytoSorb (CytoSorbents) to treat severe, refractory neurotoxicity following chimeric antigen receptor T-cell therapy.